Novel approaches and future directions in castrationresistant prostate cancer

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 1948-1957

  Nabhan, C ^a   Parsons, B ^a   Touloukian, E Z ^b   Stadler, W M ^c  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b Department of Neonatology   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Angiogenesis; Castration resistant; Immunomodulatory agents; Immunotherapy; Prostate cancer; Receptor antagonists

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CYTOTOXIC AGENT; DOCETAXEL; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MITOXANTRONE; MONOCLONAL ANTIBODY; ORTERONEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RAF PROTEIN; SATRAPLATIN; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN;

ADD ON THERAPY; CANCER CONTROL; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; NEUROPATHY; NEUTROPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 79960897914     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq639     Document Type: Review

References (127)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Maroni PD, Crawford ED. Screening for prostate cancer in 2006: PSA in the 21st century. N C Med J 2006; 67: 136-139.
3. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 167: 948-951;discussion 952.
4. Stone P, Phillips C. Management of cancer of the prostate. N Engl J Med 1995; 332: 335-336.
5. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
6. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
7. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
8. Petrylak DP. Hormone-refractory prostate cancer: new horizons. Rev Urol 2003; 5 (Suppl 6): S54-S58.
9. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
10. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-1398.
11. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-1490.
12. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgenrefractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687-1697.
13. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001; 12 (Suppl 2): S141-S144.
14. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
15. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147-155.
16. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
17. Pourmand G, Ziaee AA, Abedi AR et al. Role of PTEN gene in progression of prostate cancer. Urol J 2007; 4: 95-100.
18. Schmitz M, Grignard G, Margue C et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120: 1284-1292.
19. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgenindependent prostate cancer. Cancer Res 2007; 67: 6535-6538.
20. Khor LY, Desilvio M, Li R et al. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys 2006; 66: 25-30.
21. Yoshino T, Shiina H, Urakami S et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006; 12: 6116-6124.
22. Fox WD, Higgins B, Maiese KM et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002; 8: 3226-3231.
23. Duque JL, Loughlin KR, Adam RM et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54: 523-527.
24. Eisenberger M, Partin A. Progress toward identifying aggressive prostate cancer. N Engl J Med 2004; 351: 180-181.
25. Berthold DR, Pond GR, de Wit R et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008; 19: 1749-1753.
26. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castraterefractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-5438.
27. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
28. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
29. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
30. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxeltreated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501.
31. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castrationresistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-1488.
32. Ryan C. Androgen receptor targeted therapy. In ASCO/GU Proceedings 2010; 26-28.
33. Dreicer R, Agus DB, Macvicar G et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: a phase I/II, open-label study. In ASCO/GU Proceedings 2010; (Abstr 103).
34. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-1694.
35. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446.
36. Blackledge G. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 2003; 170: S77-S83;discussion S83.
37. Ziada A, Barqawi A, Glode LM et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60: 332-337.
38. Small EJ, Bok R, Reese DM et al. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol 2001; 28: 71-76.
39. Bonaccorsi L, Marchiani S, Muratori M et al. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 2004; 130: 604-614.
40. Canil CM, Moore MJ, Winquist E et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23: 455-460.
41. Small EJ, Fontana J, Tannir N et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007; 100: 765-769.
42. Wilding G, Soulie P, Trump D et al. Results from a pilot phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 2006; 106: 1917-1924.
43. Festuccia C, Gravina GL, Biordi L et al. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate 2009; 69: 1529-1537.
44. Nabhan C, Lestingi TM, Galvez A et al. Erlotinib has moderate single-agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial. Urology 2009; 74: 665-671.
45. Gross M, Higano C, Pantuck A et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007; 7: 142.
46. Kim HE, Han SJ, Kasza T et al. Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. Int J Radiat Oncol Biol Phys 1997; 39: 731-736.
47. George DJ. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 2002; 60: 115-121;discussion 122.
48. Lin AM, Rini BI, Weinberg V et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 2006; 98: 763-769.
49. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15: 275-286.
50. Rao K, Goodin S, Levitt MJ et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005; 62: 115-122.
51. Pietras K, Rubin K, Sjoblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476-5484.
52. Mathew P, Thall PF, Jones D et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgenindependent prostate cancer. J Clin Oncol 2004; 22: 3323-3329.
53. Lin AM, Rini BI, Derynck MK et al. A phase I trial of docetaxel/estramustine/ imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2007; 5: 323-328.
54. Koreckij T, Nguyen H, Brown LG et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009; 101: 263-268.
55. Yu EY, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-7428.
56. Kelly WK. Targeting the outlaw pathways and microenvironment in castrationresistant prostate cancer. In ASCO/GU Proceedings 2010; 29-30.
57. Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs 2002; 20: 173-182.
58. Nelson JB, Chan-Tack K, Hedican SP et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56: 663-668.
59. Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003; 170: S65-S67;discussion S67-S68.
60. Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679-689.
61. Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478-2487.
62. Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormonerefractory prostate cancer. Cancer 2007; 110: 1959-1966.
63. Nelson JB, Nabulsi AA, Vogelzang NJ et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003; 169: 1143-1149.
64. Drake JM, Danke JR, Henry MD. Bone-specific growth inhibition of prostate cancer metastasis by atrasentan. Cancer Biol Ther 2010; 9: 607-614.
65. Armstrong AJ, Creel P, Turnbull J et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008; 14: 6270-6276.
66. Lee D. Clinical trials of atrasentan in hormone-refractory prostate cancer. Clin Prostate Cancer 2003; 2: 84-86.
67. Schelman WR, Liu G, Wilding G et al. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 2009.
68. James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-1123.
69. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936.
70. Di Lorenzo G, Figg WD, Fossa SD et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 1089-1094.
71. Kelly W, Halabi S, Carducci M et al. A randomized, double-blind, placebocontrolled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrationresistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010; 28.
72. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009; 9: 263-271.
73. Tew WP, Gordon M, Murren J et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010; 16: 358-366.
74. Lockhart AC, Rothenberg ML, Dupont J et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010; 28: 207-214.
75. Isambert N, Freyer G, Zanetta S et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2008; 26.
76. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006; 407: 597-612.
77. Steinbild S, Mross K, Frost A et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97: 1480-1485.
78. Nabhan C, Tolzien K, Lestingi T et al. Activity of sorafenib (SOR) in chemotherapy-failure castration-resistant prostate cancer (CRPC). In ASCO/GU Proceedings 2010; 122: (Abstr 233).
79. Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209-214.
80. Aragon-Ching JB, Jain L, Gulley JL et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-1640.
81. Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-324.
82. Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913-920.
83. Castellano D, Gonzalez-Larriba J, Anton-Aparicio L et al. Clinical, serological, and radiographic benefit with sunitinib as a single agent in metastatic chemotherapy-resistant and hormone-refractory prostate cancer (HRPC) patients. In ASCO/GU Proceedings 2010; 121: (Abstr 229).
84. Karakunnel J, Gulley J, Arlen P et al. Cediranib (AZD2171) in docetaxelresistant, castration-resistant prostate cancer (CRPC). In ASCO Proceedings 2009; 27: (Abstr 158).
85. Sissung TM, Thordardottir S, Gardner ER, Figg WD. Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer. Anticancer Agents Med Chem 2009; 9: 1058-1069.
86. Lu L, Payvandi F, Wu L et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009; 77: 78-86.
87. Figg WD, Dahut W, Duray P et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1888-1893.
88. Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532-2539.
89. Ning YM, Figg WD, Dahut WL. Reversal of docetaxel resistance with bevacizumab and thalidomide. Clin Genitourin Cancer 2009; 7: E37-E38.
90. Amato RJ, Hernandez-McClain J, Henary H. Phase 2 study of granulocytemacrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate. Urol Oncol 2009; 27: 8-13.
91. Dreicer R, Klein EA, Elson P et al. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 2005; 23: 82-86.
92. Dahut WL, Aragon-Ching JB, Woo S et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009; 49: 650-660.
93. Mathew P, Tannir N, Tu SM et al. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 2010; 65: 811-815.
94. Nabhan C, Tolzien K, Kelby S, Lestingi T. Single agent activity of lenalidomide in chemotherapy-naive castration-resistant prostate cancer (CRPC) In ASCO/GU Proceedings 2010; 104: (Abstr 161).
95. Petrylak D, Resto-Garces K, Tibyan M, Mohile S. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 27: (Abstr 5156).
96. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6: 2175-2182.
97. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006; 6: 1163-1167.
98. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
99. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
100. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679.
101. Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010; 363: 479-481.
102. Eder JP, Kantoff PW, Roper K et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6: 1632-1638.
103. Gulley J, Chen AP, Dahut W et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgenindependent prostate cancer. Prostate 2002; 53: 109-117.
104. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-1105.
105. Madan RA, Arlen PM, Mohebtash M et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18: 1001-1011.
106. Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 2009; 9: 1565-1575.
107. Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39-44.
108. Tjoa BA, Simmons SJ, Elgamal A et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40: 125-129.
109. Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 2007; 7: 1893-1902.
110. Small E, Demkow T, Gerritsen W et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In ASCO/GU Proceedings 2009: (Abstr 7).
111. Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther 2009; 9: 231-241.
112. Small EJ, Tchekmedyian NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810-1815.
113. Mohebtash M, Madan R, Arlen P et al. Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 27: (Abstr 5144).
114. Slovin S, Beer T, Higano C et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 27: (Abstr 5138).
115. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
116. Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol 2010; 28: 1085-1087.
117. Bander NH, Nanus DM, Milowsky MI et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30: 667-676.
118. Milowsky MI, Nanus DM, Kostakoglu L et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2522-2531.
119. Wolf P, Freudenberg N, Buhler P et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010; 70: 562-569.
120. Nabhan C, Tolzien K, Lestingi T, Bitran J. Effect of GM-CSF maintenance in patients (pts) with castration-resistant prostate cancer (CRPC) who maximized their response to chemotherapy (chemo) on biochemical response In ASCO/GU Proceedings 2010; 124: (Abstr 242).
121. Small EJ, Beer T, Weinberg V et al. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): results of a prospective randomized phase II trial of the department of Defense Prostate Cancer Clinical Trials Consortium In ASCO/GU Proceedings 2010; 74: (Abstr 41).
122. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-556.
123. Fizazi K, Carducci M, Smith M et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castrationresistant prostate cancer. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 28: (LBA4507).
124. Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-594.
125. Boysen M, Longson C, Stevens A. Erlotinib for the treatment of non-small-cell lung cancer. Lancet Oncol 2009; 10: 15-16.
126. Nadiminty N, Dutt S, Tepper C, Gao AC. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate 2010; 70: 276-287.
127. Setlur SR, Royce TE, Sboner A et al. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 2007; 67: 10296-10303.